Masterclass series in peripheral arterial disease

Chobanian AV , Bakris GL , Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2571.

Cherry DK , Woodwell DA. National ambulatory medical care survey: 2000 summary. Adv Data 2002; 328: 1-32.

Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure . The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.

Black HR , Elliott WJ , Neaton JD et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 2001; 37: 12-18.

Cushman WC , Ford CE , Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.

Selvin E , Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738-743.

Meijer WT , Hoes AW , Rutgers D , Bots ML , Hofman A , Grobbee DE. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998; 18: 185-192.

Hirsch AT , Criqui MH , Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.

McDermott MM , Mehta S , Ahn H , Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997; 12: 209-215.

Brevetti G , Oliva G , Silvestro A , Scopacasa F , Chiariello M. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis 2004; 175: 131-138.

Diehm C , Schuster A , Allenberg JR et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004; 172: 95-105.

Fowkes FG , Housley E , Riemersma RA et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992; 135: 331-340.

Makin A , Lip GY , Silverman S , Beevers DG. Peripheral vascular disease and hypertension: a forgotten association? J Hum Hypertens 2002; 15: 447-454.

Heidrich H. Frequency of non-vascular accompanying diseases in patients with peripheral arterial disease. VASA 2004; 33: 155-158.

Newman AB , Sutton-Tyrrell K , Vogt MT , Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA 1993; 270: 487-499.

Newman AB , Siscovick DS , Manolio TA et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993; 88: 837-845.

Kannel WB , McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33: 13-18.

Kannel WB , McGee DL , Schwartz MJ , Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation 1970; 41: 875-883.

Olin JW , Melia M , Young JR , Graor RA , Risius B. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990; 88(1N): 46N-51N.

Scoble JE. The epidemiology and clinical manifestations of atherosclerotic renal artery disease. In: Novick AC , Scoble J , Hamilton G eds. Renal vascular disease. London: WB Saunders, 1996: 303-314.

Missouris CG , Buckenham T , Cappuccio FP , MacGregor GA. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med 1994; 96: 10-14.

Olin JW , Begelman SM. Renal artery disease. In: Topol E ed. Textbook of cardiovascular medicine. Philadelphia, PA: Lippincott Raven, 2002: 2139-2159.

Rimmer JM , Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med 1993; 118: 712-719.

Gray BH , Olin JW , Childs MB , Sullivan TM , Bacharach JM. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med 2002; 7: 275-279.

Lewington S , Clarke R , Qizilbash N , Peto R , Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.

Vogt MT , Cauley JA , Newman AB , Kuller LH , Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465-469.

Newman AB , Tyrrell KS , Kuller LH. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc 1997; 45: 1472-1478.

Zheng ZJ , Sharrett AR , Chambless LE et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997; 131: 115-125.

Leng GC , Lee AJ , Fowkes FG et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25: 1172-1181.

Neal B , MacMahon S , Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356: 1955-1964.

SHEP Cooperative Research Group . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.

Dahlof B , Lindholm LH , Hansson L , Schersten B , Ekbom T , Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.

Clement DL , De Buyzere ML , Duprez DA. Hypertension in peripheral arterial disease. Curr Pharm Des 2004; 10: 3615-3620.

Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621.

The Treatment of Mild Hypertension Research Group (TOMHS) . The treatment of mild hypertension study. A randomized placebo controlled trial of a nutrional hygienic regimen with various drug monotherapies. Arch Intern Med 1991; 151: 1413-1423.

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) . ALLHAT Collaborative Research Group. JAMA 2000; 283: 1967-1975.

Whelton SP , Chin A , Xin X , He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136: 493-503.

Stewart KJ , Hiatt WR , Regensteiner JG , Hirsch AT. Exercise training for claudication. N Engl J Med 2002; 347:1941-1951.

Radack K , Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151:1769-1776.

Heintzen MP , Strauer BE. Peripheral vascular effects of beta-blockers. Eur Heart J 1994; 15 (Suppl C): 2-7.

Coffman JD , Rasmussen HM. Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud’s phenomenon. Circulation 1985; 72: 466-470.

Rustin MH , Newton JA , Smith NP , Dowd PM. The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial. Br J Dermatol 1989; 120: 267-275.

Mehler PS , Coll JR , Estacio R , Esler A , Schrier RW , Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753-756.

The Heart Outcomes Prevention Evaluation Investigators . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342:145-153.

Stumpe KO. Antihypertensive therapy: new strategies beyond blood pressure control. J Cardiovasc Pharmacol 1992; 20(Suppl 6): 1-4.

Fox KM , Henderson JR , Bertrand ME , Ferrari R , Remme WJ , Simoons ML. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998; 19(Suppl J): 52-55.

Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.

Navalkar S , Parthasarathy S , Santanam N , Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-444.

Prasad A , Narayanan S , Waclawiw MA , Epstein N , Quyyumi AA. The insertion/deletion polymorphism of the angiotensin-converting enzyme gene determines coronary vascular tone and nitric oxide activity. J Am Coll Cardiol 2000; 36: 1579-1586.

Dahlof B , Devereux RB , Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.

Pfeffer MA , Swedberg K , Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.

Rosner MH , Okusa MD. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Arch Intern Med 2003; 163:1025-1029.